Bi-specific antigen-binding polypeptides
The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.
1. An isolated bi-specific antigen-binding polypeptide comprising an antibody heavy chain comprising a first VH domain that specifically binds to human HER2, wherein the heavy chain is C-terminally linked to a second VH domain that specifically binds to human PDGFRβ, wherein the polypeptide is devoid of antibody light chains, and wherein the VH domain that binds specifically to human HER2 comprises:
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 1,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 2, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 3; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 8, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 9; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 11, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12.
2. The antigen-binding polypeptide of claim 1 , wherein the antibody heavy chain is genetically linked to the second VH domain through an amino acid linker.
3. The antigen-binding polypeptide of claim 1 , wherein the VH domain that binds specifically to human PDGFRβ comprises:
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 25,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 27.
4. The antigen-binding polypeptide of claim 3 , comprising a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 24.
5. The antigen-binding polypeptide of claim 2 , wherein the linker comprises the amino acid sequence set forth in SEQ ID NO: 23.
6. The antigen-binding polypeptide of claim 1 , comprising a VH domain amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16.
7. The antigen-binding polypeptide of claim 3 , comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 18 or SEQ ID NO: 20.
8. An antigen-binding polypeptide comprising a dimer of two antigen-binding polypeptides of claim 1 , wherein the two antigen-binding polypeptides are naturally dimerized through constant regions of the heavy chains.
9. A pharmaceutical composition comprising the antigen-binding polypeptide of claim 1 and one or more pharmaceutically acceptable carrier.
10. An isolated bi-specific antigen-binding polypeptide comprising an antibody heavy chain comprising a first VH domain that specifically binds to human HER2 and a CH1 domain, wherein the first VH domain amino acid sequence is selected from the group consisting of SEQ ID NOs: 13, 14, 15 and 16, wherein the heavy chain is C-terminally linked to a second VH domain that specifically binds to human PDGFRP, and further comprising an antibody light chain, wherein the light chain comprises a VL domain that specifically binds to human PDGFRP and a CL domain, and comprises: a LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 29, a LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and a LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 31, wherein the heavy and light chains are naturally paired.
11. The antigen-binding polypeptide of claim 10 , comprising a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 28, or comprising an antibody light chain comprising the amino acid sequence set forth in SEQ ID NO: 22.
12. An isolated bi-specific antigen-binding polypeptide that specifically binds to human PDGFRβ and HER2 comprising a VH domain amino acid sequence sharing at least %98% amino acid sequence identity with a VH domain amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16.
13. An isolated antigen-binding polypeptide that specifically binds to human HER2, comprising:
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 1,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 2, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 3; or
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 4,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 5, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 6; or
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 7,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 8, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 9; or
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 10,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 11, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 12.
14. An isolated antigen binding polypeptide comprising a VH domain amino acid sequence sharing at least %98% amino acid sequence identity with a VH domain amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16.